Last $115.46 USD
Change Today -0.08 / -0.07%
Volume 3.2M
AMGN On Other Exchanges
Symbol
Exchange
Hong Kong
Mexico
NASDAQ GS
Sao Paulo
Frankfurt
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

amgen inc (AMGN) Snapshot

Open
$115.61
Previous Close
$115.54
Day High
$117.19
Day Low
$115.02
52 Week High
03/21/14 - $128.96
52 Week Low
06/6/13 - $94.15
Market Cap
87.3B
Average Volume 10 Days
4.8M
EPS TTM
$7.31
Shares Outstanding
756.5M
EX-Date
05/13/14
P/E TM
15.8x
Dividend
$2.44
Dividend Yield
1.75%
Current Stock Chart for AMGEN INC (AMGN)

amgen inc (AMGN) Details

Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. Its principal products include Neulasta, a pegylated protein for the treatment of chemotherapy-induced febrile neutropenia; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for treating the patients with non-myeloid malignancies; and Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. The company’s principal products also comprise Aranesp and EPOGEN erythropoiesis-stimulating agents for the treatment of anemia and dialysis; XGEVA and Prolia for the prevention of skeletal-related events and treatment of postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. Its other marketed products include Nplate, a thrombopoietic compound; and Vectibix, a human monoclonal antibody. The company’s products in phase 3 clinical trial comprise Evolocumab, a human monoclonal antibody used for the treatment for dyslipidemia; Talimogene Laherparepvec for the treatment of unresected stage IIIB, IIIC, or IV melanoma; and Trebananib for the treatment of ovarian cancer. Its other product in development stage includes Ivabradine, an oral drug for chronic heart failure and stable angina in patients with elevated heart rates. The company markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and pharmaceutical wholesale distributors. It has collaborative arrangements with Pfizer Inc.; Glaxo Group Limited; AstraZeneca Plc.; Takeda Pharmaceutical Company Limited; UCB; and Bayer HealthCare Pharmaceuticals Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

20,000 Employees
Last Reported Date: 02/24/14
Founded in 1980

amgen inc (AMGN) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $1.5M
Executive Vice President of Operations
Total Annual Compensation: $1.1M
Executive Vice President of Global Commercial...
Total Annual Compensation: $1.0M
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $845.9K
Executive Vice President of Research & Develo...
Total Annual Compensation: $896.5K
Compensation as of Fiscal Year 2013.

amgen inc (AMGN) Key Developments

Amgen Inc. to Terminate Licensing Agreement with Kyowa Hakko Kirin Co., Ltd

Kyowa Hakko Kirin Co. Ltd. announced KHK and Amgen Inc. will terminate their licensing agreement in relation to mogamulizumab. Under the licensing agreement entered into on March 6, 2008, Amgen was granted exclusive rights to develop and commercialize Kyowa Hakko Kirin's humanized monoclonal antibody mogamulizumab in all non-oncology indications worldwide, except in Japan, China, Korea and Taiwan. After entering into the agreement, Amgen conducted clinical trials aimed at patients with asthma. Kyowa Hakko Kirin has completed a Phase 1 clinical trial in healthy Japanese adults, and will determine its future development policy after carefully considering the outcome of the Phase 1 results. The termination of the agreement will have a minimal effect on Kyowa Hakko Kirin's financial results (fiscal term ending December 2014).

Amgen Inc. Announces Resignation of Thomas J.W. Dittrich as its Vice President, Finance and Chief Accounting Officer, Effective August 2, 2014

On April 7, 2014, Thomas J.W. Dittrich informed Amgen Inc. that, effective August 2, 2014, he will resign as its Vice President, Finance and Chief Accounting Officer to pursue an opportunity to serve as the Chief Financial Officer of a Swiss-based company.

Amgen Provides Update on Phase 3 Study of Talimogene Laherparepvec in Patients with Metastatic Melanoma

Amgen announced top-line results from the primary overall survival (OS) analysis of a Phase 3 trial in melanoma, which evaluated the efficacy and safety of talimogene laherparepvec for the treatment of unresected stage IIIB, IIIC or IV melanoma compared to treatment with subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF). Results showed that, while the primary end point of durable response rate was met (as previously reported), the secondary endpoint of OS was not met, although there was a strong trend in favor of talimogene laherparepvec. The estimated OS hazard ratio and improvement in median OS were similar to what was previously reported at the interim OS analysis. Talimogene laherparepvec is an investigational oncolytic immunotherapy designed to selectively replicate in tumors and to initiate an immune response to target cancer that has metastasized, or spread to other areas of the body. The global, randomized, open-label Phase 3 trial enrolled patients with unresected stage IIIB, IIIC or IV melanoma. Patients were randomized 2:1 to receive either talimogene laherparepvec every two weeks through direct tumor injection or GM-CSF subcutaneously for the first 14 days of each 28-day cycle, for up to 18 months. The most frequent adverse events observed in this trial were fatigue, chills and pyrexia. The most common serious adverse events include disease progression, cellulitis and pyrexia.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AMGN:US $115.46 USD -0.08

AMGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $48.55 USD +0.43
AstraZeneca PLC 3,782 GBp +23.00
Bristol-Myers Squibb Co $49.46 USD +0.35
Eli Lilly & Co $60.43 USD +0.47
Novo Nordisk A/S kr235.60 DKK +4.90
View Industry Companies
 

Industry Analysis

AMGN

Industry Average

Valuation AMGN Industry Range
Price/Earnings 17.4x
Price/Sales 4.7x
Price/Book 3.9x
Price/Cash Flow 17.2x
TEV/Sales 1.9x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMGEN INC, please visit www.amgen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.